1 / 25

Arginine Vasopressin in Advanced Vasodilatory Shock A Prospective, Randomized, Controlled Study

Arginine Vasopressin in Advanced Vasodilatory Shock A Prospective, Randomized, Controlled Study. Circulation. 2003;107:2313-2319. Vasodilatory shock - siginificantly decreased systemic vascular resistance -> low arterial blood pressure

edison
Download Presentation

Arginine Vasopressin in Advanced Vasodilatory Shock A Prospective, Randomized, Controlled Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Arginine Vasopressin in Advanced Vasodilatory Shock A Prospective, Randomized, Controlled Study Circulation. 2003;107:2313-2319.

  2. Vasodilatory shock - siginificantly decreased systemic vascular resistance -> low arterial blood pressure • Sepsis, cardiopulmonary bypass가 필요한 cardiovascular surgery - most frequent cause (any origin of shock -> massive vasodilatation) • Adequate therapy 1) specific treatment of the underlying disease 2) volume resuscitation 3) use of vasopressor

  3. Catecholamines - clinically used vasopressor agents of choice - supporting arterial blood pressure + ensuring adequate organ prefusion • Adrenergic hyposensitivity -> a feared complication • Progressively increasing catecholamine therapy -> catecholamine의 사용을 더욱 증가시키는 방향으로 상황을 악화시킬 수 있음 (major adverse side effects의 증가) • 이런 상황에서 mortality는 거의 100%에 가깝다 • 그러므로 catecholamine excess의 상황에서 cardiocirculatory function을 안정화 시킬 수 있는 vasopressor agents의 사용은 큰 이득이 됨

  4. Arginine vasopressin (AVP) - potent endogenous vasopressor hormone of the neurohypophysis • Case reports and small clinical trials - continuous infusion of AVP can reverse hypotension in catecholamine-resistant vasodilatory shock • Unfortunately, little is known about possible adverse side effects of AVP used for this indication • In particular, gastrointestinal hypoperfusion (common complication of severe critical illness) may be aggravated by AVP

  5. A prospective, randomized, controlled study to evaluate differences in hemodynamic response and organ functions in patients with advanced vasodilatory shock receiving either a combined infusion of AVP and norepinephrine(NE) or NE alone

  6. Methods Patients • 48 critically ill patients suffering from vasodilatory shock (cardiovascular surgery, systemic inflammatory response syndrome, sepsis) • MAP < 70 mmHg despite adequate volume resuscitation • NE requirements exceeding 0.5 μg/kg/min • Invasively monitored

  7. Fluid loading에 대한 stroke volume의 반응을 보면서 volume resuscitation을 시행 • 반복된 colloid 투여에도 stroke volume이 상승하지 않으면 normovolemia 인 것으로 가정 • Stroke volume이 최대일 때의 PCWP가 further volume resuscitation의 치료 목표치로 사용됨 • stroke volume index < 25 mL/min/m2 or cardiac index < 2 L/min/m2 -> milrinone infusion 시작 (0.3-0.6 μg/kg/min)

  8. Study design

  9. Study End Points 1) 48시간 동안의 두 군 간 hemodynamics 차이를 조사 2) single-organ function의 변화를 조사

  10. Demograpahic data • ASA classification • Admission Dx • ICU에 입원한 후 처음 24시간 동안의 Simplified Acute Physiological Score Ⅱ • Worst clinical and laboratory data -> modified Goris Multiple Organ Dysfuction Syndrome Score를 계산 • Length of ICU stay • ICU mortality

  11. Hemodynamics • Heart rate • MAP • Mean pulmonary arterial blood pressure • Pulmonary capillary wedge pressure • Cardiac and stroke volume indices • NE and milrinone requirements (before study entry and at 1, 12, 24, and 48 hours after study entry) • Systemic vascular resistance index • Left ventricular stroke work index (LVSWI) • Systemic oxygen transport index • Systemic oxygen consumption index

  12. Incidence and types of new-onset tachyarrhythmias were monitored during the study • Tachyarrhythmias - non sinus rhythm with heart rates exceeding 100 bpm • Twelve-lead ECG examinations and serum troponin I determinations were performed to scan for myocardial ischemia or infarction

  13. Single-Organ Functions • Gut mucosal PCO2 (PrCO2) + PrCO2 to arterial PCO2 gradient (Pr-aCO2) -> indicators of splanchnic perfusion • Arterial acid/base status + Arterial lactate concentrations • PaO2/FiO2 quotient • Serum concentrations of creatinine, aspartate aminotransferase, alanine aminotransferase, total bilirubin, and platelet count

  14. Results

  15. Hemodynamics

  16. Significant difference in the incidence of new-onset tachyarrhythmias between groups - 2 of 24 patients (8.3%) receiving AVP -> new-onset tachycardic AF - 14 of 24 NE patients (54.3%) -> new-onset tachycardic AF • No differences in the incidence of myocardial ischemia and myocardial infarction between groups - 2 NE patients -> myocardial ischemia - 1 NE patient -> myocardial infarction • No differences in troponin I values between AVP and NE patients

  17. Single-Organ Functions • One patient of the NE group died of total intestinal ischemia and necrosis during the study period

  18. Discussion • Combined infusion of AVP and NE -> an effective vasopressor regimen to treat cardiocirculatory failure in patients with catecholamine-resistant vasodilatory shock (higher MAP, cardiac index, stroke volume index, and LVSWI and needed less vasopressor support)

  19. AVP-induced intense constriction of peripheral resistance vessels -> significantly higher MAP • In arteriolar smooth muscle cells, stimulation of V1a-receptors -> an increase in cytoplasmatic ionized calcium -> vasoconstriction. • Unlike catecholamine-mediated vasoconstriction, vasopressor effects of AVP -> preserved during hypoxia and acidosis

  20. In vasodilatory shock, AVP는 vasodilatation의 pathogenesis와 관련된 several mechanisms에 영향을 줌 1) blockage of ATP-activated potassium channels 2) attenuation of nitric oxide production 3) reversal of adrenergic receptor downregulation

  21. Recent investigations에 의하면, patients with vasodilatory shock -> inadequately low AVP serum concentrations • Deficiency of endogenous AVP -> may contribute to loss of vascular tone 1) dysfunction of the baroreceptor reflex 2) inhibition of AVP production 3) depletion of AVP stores during sustained hypotension • Infusion of AVP -> reverse AVP deficiency restore endogenous vasopressor effects

  22. Patients receiving AVP -> significantly better myocardial performance • Several mechanisms 1) significantly lower NE dosages (cardiotoxic and proarrhythmic effects) -> lower incidence of tachyarrhythmias 2) attenuate endotoxin- and interleukin-1β-stimulated generation of nitric oxide -> possibly reversing negative inotropic effects of cardiodepressant mediators 3) stimulation of V1a-receptors -> increases intracellular calcium in myocardial cells -> a direct positive inotropic response 4) increased systemic perfusion pressure and selective coronary vasodilatation -> increase myocardial blood flow

  23. Significantly lower incidence of new-onset tachyarrhythmias <- significant reduction in NE dosages + improvement of myocardial blood flow • Gastrointestinal perfusion - significantly better - UGI bleeding에서나 catecholamine-resistant hypotension 시 AVP therapy가gastrointestinal blood flow를 현저히 감소시킬 수 있다는 보고와는 상반된 결과 • Bolus injections and high AVP dosages have been applied in these studies <-> AVP dosages in this protocol never exceeded 4U/h • In low dosages, AVP-mediated vasodilatation of the splanchnic vascular bed has been reported

  24. Total bilirubin concentrations 증가 • Septic과 postcardiotomy shock에서 total bilirubin의 현저한 증가는 이미 보고되었지만, AVP로 인한 직접적인 hepatic dysfunction에 대해서는 보고된 적이 없음 • Possible mechanisms 1) AVP-mediated reduction in hepatic blood flow 2) direct impairment of hepatocellular function

  25. Combined infusion of AVP and NE proved to be superior - Significantly higher blood pressure - Improved cardiac performance - Needed less NE - Reduce cardiotoxic effects of high catecholamine dosages (new-onset tachyarrhythmias) - Gastrointestinal perfusion seemed to be better preserved • 하지만 catecholamine-resistant vasodilatory shock 환자의 mortality와 morbidity에 대한 combined infusion regimen (AVP+NE) 의 장점을 조사하기 위해서는 larger study가 필요함

More Related